Breast Cancer | Specialty

mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast Cancer

March 27th 2015

The role of mTOR inhibition in breast cancer is evolving, and ongoing studies are evaluating biomarkers that will identify the patients who will benefit.

Baylor Sammons Cancer Center Provides Patient-Centered Care

March 26th 2015

BEACON Trial Results, Diet, Obesity, and More

March 26th 2015

Hope Rises for Immunotherapy in Breast Cancer

March 25th 2015

Elizabeth A. Mittendorf, MD, PhD, differentiates the main types of immunotherapy, highlights some of the most interesting results in breast cancer trials, and discusses why different types of immunotherapy might be appropriate for different types of breast tumors at various stages of development.

Dr. Sledge on Using PCR To Determine Therapy Benefit for Breast Cancer

March 24th 2015

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine discusses the benefits of using pathological complete response rate (PCR) to understand therapy benefit in breast cancer.

Pegram Discusses Optimal Pertuzumab Use in HER2-Positive Breast Cancer

March 24th 2015

In an interview with OncLive, Mark D. Pegram, MD, discusses what available data suggest is the optimal use of pertuzumab for the management of HER2-positive breast cancer.

Evolving Role of Lymph Node Biopsies After Neoadjuvant Therapy for Breast Cancer

March 23rd 2015

OncLive spoke with Kelly K. Hunt, MD, about how breast cancer interventions have progressed in the adjuvant and neoadjuvant setting and about the role of sentinel lymph node dissection in the neoadjuvant setting.

Lapatinib Falls Short Versus Trastuzumab, Adding Clarity to Frontline HER2-Positive MBC Strategy

March 20th 2015

First-line treatment with lapatinib and a taxane failed to improve progression-free survival versus trastuzumab plus a taxane in patients with HER2-positive metastatic breast cancer in the MA.31 trial.

BEACON Breast Cancer Study Falls Short, Focus Shifts to Subgroups With Brain or Liver Mets

March 19th 2015

In the phase III BEACON trial, etirinotecan pegol missed the primary endpoint of significantly extending overall survival versus physician's choice of therapy.

How to Involve Community Oncologists in Molecular-Based Research-and Expedite Results

March 13th 2015

What if a negative study had been made available through a secure online registry where patients could sign up, with the assistance of their own oncologists?

Hopkins Researcher Describes Evolving Challenges of Targeting PI3K in Breast Cancer

March 12th 2015

Josh D. Lauring, MD, PhD, of Johns Hopkins Medicine, discusses efforts to develop breast cancer therapies by targeting the PI3K pathway.

Dr. Pegram on Neoadjuvant Treatments for HER2-Postive Breast Cancer

March 11th 2015

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses optimizing neoadjuvant treatments for HER2-positive breast cancer.

Top Breast Cancer Research Findings for the Past Year

March 9th 2015

A new standard that recommends ovarian function suppression (OFS) therapy as a routine adjuvant treatment option for certain premenopausal women with higher risk, hormone receptor (HR)–positive breast cancer emerged as the most far-reaching medical oncology research finding in the field for 2014, according to Debu Tripathy, MD.

Dr. Schilling on Dense Breast Tissue Detection Methods

March 6th 2015

Kathy J. Schilling, MD, a radiologist at Boca Raton Regional Hospital, discusses the importance of additional screening for women with dense breasts.

Balancing Act: Calculating Adjuvant Treatment Risks in Older Women With Breast Cancer

March 6th 2015

Hyman B. Muss, MD, provides expert insight on adjuvant treatment for older patients with breast cancer.

Carey Offers Views on Evolving Chemotherapy Options-and Beyond-in TNBC

March 5th 2015

OncLive spoke with Lisa A. Carey, MD, professor at the University of North Carolina Chapel Hill, about recent developments for patients with triple-negative breast cancer.

Dr. Schilling on Screening for Breast Cancer

March 4th 2015

Kathy Schilling, MD, radiologist, Christine E. Lynn Women's Health & Wellness Institute at Boca Raton Regional Hospital, discusses screening methods for breast cancer.

Dixon Questions Value of Chemoprevention With Tamoxifen

March 3rd 2015

The reduction of breast cancer risk with 5 years of tamoxifen does not outweigh the lack of a mortality benefit, according to J. Michael Dixon, MD, OBE, who shared his view in a session at the 32nd Annual Miami Breast Cancer Conference.

Top MBCC Abstracts Focus on Tumor Profiling and Radiotherapy Paradigms

March 2nd 2015

A detailed tumor profile of molecular and protein alterations in a rare breast cancer subtype and a retrospective analysis about the impact of radiation after breast conserving surgery took home top honors at the Miami Breast Cancer Conference this year.

US Lags in Adopting Hypofractionated Radiation Standard

March 2nd 2015

Compelling clinical trial evidence supports the use of hypofractionated radiation as the standard of care for postmenopausal women with luminal A tumors and node-negative disease.